Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0015 USD | 0.00% | 0.00% | +15.38% |
Aug. 25 | Motion for De Minimus Asset Sale Approved for HTG Molecular Diagnostics, Inc. | CI |
Aug. 16 | Motion for De Minimus Asset Sale Filed by HTG Molecular Diagnostics, Inc. | CI |
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+15.38% | 3.32K | - | - | |
-34.48% | 3.23B | C+ | ||
+12.43% | 1.79B | - | - | |
-0.43% | 1.67B | - | ||
+36.05% | 1.38B | B+ | ||
-3.90% | 1.11B | - | ||
-19.15% | 915M | - | C- | |
-6.11% | 738M | - | ||
-11.46% | 716M | B+ | ||
+12.74% | 537M | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock
- Equities
- Stock HTG Molecular Diagnostics, Inc. - OTC Markets
- Ratings HTG Molecular Diagnostics, Inc.